These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1500491)

  • 41. [Evaluation and treatment of adolescent girls with hirsutism].
    Bumbuliene Z; Alisauskas J
    Ginekol Pol; 2009 May; 80(5):374-8. PubMed ID: 19548458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Can one prove a relationship between hirsutism and the morphological changes in the polycystic ovary?].
    Csaba I; Bücs G
    Acta Med Acad Sci Hung; 1969; 26(1):47-56. PubMed ID: 5793284
    [No Abstract]   [Full Text] [Related]  

  • 43. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.
    Azziz R; Ochoa TM; Bradley EL; Potter HD; Boots LR
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3406-11. PubMed ID: 8530573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of gonadotropin-releasing hormone agonist on body composition in a patient with polycystic ovary syndrome.
    Douchi T; Yamasaki H; Oki T; Andoh I; Kuwahata R; Nagata Y
    Acta Obstet Gynecol Scand; 2000 Jul; 79(7):608-9. PubMed ID: 10929964
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment with GnRH analogs in polycystic ovarian disease. A collaborative multicenter study. The preliminary results].
    Cipolla L; Zagni R; Ferrante B; Giannetta G; Soliani A
    Minerva Ginecol; 1994 Mar; 46(3):85-9. PubMed ID: 8015704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term suppression of testosterone after treatment with a gonadotropin-releasing hormone agonist in a woman with a presumed testosterone secreting ovarian tumor.
    Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1746-8. PubMed ID: 9177374
    [No Abstract]   [Full Text] [Related]  

  • 47. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
    Ruan X; Kubba A; Aguilar A; Mueck AO
    Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Polycystic ovary syndrome and hair unit function disturbances in dermatological practice].
    Szpringer EA; Lutnicki KR; Zych IS
    Wiad Lek; 2006; 59(11-12):848-54. PubMed ID: 17427503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Liraglutide in polycystic ovary syndrome].
    Gómez-Pérez AM; Fernández-García JC; Mancha Doblas I; Tinahones FJ
    Med Clin (Barc); 2014 Sep; 143(6):283-4. PubMed ID: 24456922
    [No Abstract]   [Full Text] [Related]  

  • 50. [The differential diagnosis of hairy virilism in polycystic ovaries from adrenal cortical hirsutism].
    Maleeva A; Milkov V; Visheva N; Kekhaĭova M
    Vutr Boles; 1990; 29(3):93-9. PubMed ID: 2178292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
    Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
    J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hirsutism.
    Mauvais-Jarvis P; Kuttenn F; Mowszowicz I
    Monogr Endocrinol; 1981; 19():1-116. PubMed ID: 6454061
    [No Abstract]   [Full Text] [Related]  

  • 53. [Hirsutism].
    van Zuuren EJ; Pijl H
    Ned Tijdschr Geneeskd; 2007 Oct; 151(42):2313-8. PubMed ID: 18064932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation and therapy of polycystic ovarian syndrome.
    Loy R; Seibel MM
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):785-813. PubMed ID: 3143568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome.
    Guzel AI; Kuyumcuoğlu U; Celik Y
    Arch Gynecol Obstet; 2012 Mar; 285(3):767-70. PubMed ID: 21909749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinical evaluation of hirsutism.
    Somani N; Harrison S; Bergfeld WF
    Dermatol Ther; 2008; 21(5):376-91. PubMed ID: 18844715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents.
    Villarroel C; López P; Merino PM; Iñiguez G; Sir-Petermann T; Codner E
    Gynecol Endocrinol; 2015; 31(8):625-9. PubMed ID: 26190534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hirsutism: diagnosis and management.
    Mercurio MG
    J Gend Specif Med; 2001; 4(2):29-34, 64. PubMed ID: 11480095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical presentation and etiologic factors of hirsutism in premenopausal Iranian women.
    Ansarin H; Aziz-Jalali MH; Rasi A; Soltani-Arabshahi R
    Arch Iran Med; 2007 Jan; 10(1):7-13. PubMed ID: 17198446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Presentation of severe hirsutism in a young woman with polycystic ovary syndrome.
    Łebkowska A; Naronowicz G; Sokolowska G; Szerenos E; Karczewska-Kupczewska M; Kowalska I
    Pol Arch Intern Med; 2021 Oct; 131(10):. PubMed ID: 34223745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.